Atlas Trials

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

Clinical trial NCT05165355 · UNKNOWN

Trial details

NCT number
NCT05165355
Sponsor
Tongji University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLCEGF-R Positive Non-Small Cell Lung Cancer
Start date
2021-12-28
Primary completion
2024-11-01
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.